ARdVRk Technologies

Augmented Reality platform for medical education and training of patients and physiciansARdVRk's mission is to increase patient and Health Care Professional engagement to help them better understand (education and training) and retain information related to drug therapies and medical devices.  Biopharmaceutical and device companies today face a number of key challenges:Inability of physicians and nurses to stay current on new therapies and treatment protocolsInsufficient healthcare literacy for patients and caregivers to make informed decisionsLow enrollment by screened patients in clinical trialsDeclining physician accessLimited patient engagement To address these challenges, ARdVRk has developed a scalable and configurable avatar platform, Vital Recall®, that has demonstrated better engagement of patient and Health Care Professionals than the currently available engagement models.  This provides our clients with an ability to drive:Faster and cheaper clinical trials through higher clinical trial enrollment and lower attrition rates as well as improved adherence to clinical trial protocolsImproved peer-to-peer conversations through better training of Medical Affairs staffIncreased drug/device sales through increased physician access and treatment adherence and loyalty Our Vital Recall® SaaS (Software as a Service) platform is currently in the field, generating revenue, with some of the largest biopharmaceutical and device companies like Becton Dickinson and CSLBehring.  Revenue increased by more than 65% in 2019 to $435K and are projecting 2020 revenue of $1M and 2023 revenue of $5M.

2019 revenue of $435k represents over 69% YoY growth and the product is currently deployed in the US, China, and the UK
Clients include major biopharmaceutical and device clients such as AstraZeneca, Becton Dickinson, and CSL Behring
Founders and management have over 40 years of combined experience, including executive roles in the life science industry at AstraZeneca, McKinsey, and others
Notable investors include Warren Thaler, former President of Gund Investments and current investor and board member of Align Technologies, and James Lovett, CEO of Myoderm and former SVP of Covance
Notable advisors include Bill Mezzanotte, Executive Vice President, Head Research & Development at CSL Behring

Sales & Biz Dev: 35%

Platform Build-Out: 55%

General Corporate: 10%

Elgar Peerschke
CEO
Over 25 years experience in the life sciences industry, first as a partner at McKinsey & Company and subsequently as a senior partner and Global Healthcare Practice Leader at Bain & Company.  Prior to becoming CEO of ARdVRk he was SVP of Customer Relations at IQVIA, a leading global health information technology and clinical research company.

Chris McClellan
Chief Technology Officer
Over 15 years of experience as a software developer specializing in augmented and virtual reality.  He has a background in biomedical engineering and significant experience with training and simulation applications.

John O'Brien
Chairman of the Board
Over 30 years in the pharmaceutical industry holding various senior leadership roles at AstraZeneca - Head of Oncology, SVP Portfolio Review Board.

Round type: Seed Round size: US $2,500,000 Minimum investment: US $1,000 Target Minimum: US $500,000 Raised to date: US $100,000 US $0 (under Reg CF only) Security Type: Crowd Note Conversion discount: 20.0% Interest rate: 5.0% Note term: 36 months